Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer

Table 1 Correlation between endocan-microvessel density and clinicopathological features and vascular endothelial growth factor/vascular endothelial growth factor receptor 2 expression in gastric cancer

Clinicopathologic feature	n	Endocan-MVD	P value1
Gender			0.27
Male	93	18.19 ± 8.240
Female	49	19.79 ± 8.203
Age (yr)			0.32
< 60	78	19.36 ± 8.436
≥ 60	64	18.00 ± 7.982
Tumour size (cm)			0.000a
< 5	79	16.48 ± 9.170
≥ 5	63	21.58 ± 5.799
Borrmann type			0.000a
I	18	11.33 ± 3.970
II	15	11.93 ± 4.651
III	81	21.17 ± 8.122
IV	28	20.14 ± 7.437
Histology			0.25
Adenocarcinoma	118	19.11 ± 8.183
Signet ring cell carcinoma	8	16.55 ± 2.554
Mixed carcinoma	15	17.13 ± 10.602
Differentiation			0.000a
High/moderate	36	11.66 ± 4.623
Low/undifferentiated	106	21.15 ± 7.803
Tumour invasion			0.000a
T1	2	6.33 ± 0.577
T2	30	10.30 ± 4.822
T3	4	16.33 ± 0.577
T4	106	21.56 ± 7.168
Lymph node metastasis			0.000a
N0	33	12.60 ± 7.314
N1	21	17.521 ± 5.662
N2	30	16.96 ± 7.420
N3	58	23.62 ± 7.053
TNM stage			0.000a
I	15	8.80 ± 3.764
II	18	11.38 ± 5.679
III	99	20.85 ± 7.331
IV	10	26.10 ± 2.960
VEGF expression			0.001a
Negative	58	16.32 ± 6.227
Positive	84	20.43 ± 9.015
VEGFR2 expression			0.000a
Negative	66	12.48 ± 5.239
Positive	76	24.19 ± 6.222

¹Student t-test;

^aP < 0.05, statistically significant. VEGF: Vascular endothelial growth factor; VEGFR2: VEGF receptor 2; MVD: Microvessel density.